vs
Side-by-side financial comparison of Ambow Education Holding Ltd. (AMBO) and BioLineRx Ltd. (BLRX). Click either name above to swap in a different company.
BioLineRx Ltd. is the larger business by last-quarter revenue ($5.4M vs $2.8M, roughly 1.9× Ambow Education Holding Ltd.). Ambow Education Holding Ltd. runs the higher net margin — 64.2% vs 9.0%, a 55.2% gap on every dollar of revenue.
Ambow Education Holding Ltd. is a China-focused education service provider that offers personalized learning solutions, professional career training programs, and K-12 after-school tutoring services. It partners with educational institutions and enterprises to deliver technology-integrated learning resources for learners of all age groups across mainland China.
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
AMBO vs BLRX — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $2.8M | $5.4M |
| Net Profit | $1.8M | $484.0K |
| Gross Margin | 53.3% | 83.4% |
| Operating Margin | 11.9% | -107.0% |
| Net Margin | 64.2% | 9.0% |
| Revenue YoY | 15.3% | — |
| Net Profit YoY | 1343.1% | 102.6% |
| EPS (diluted) | $0.03 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $2.8M | — | ||
| Q2 24 | $2.4M | $5.4M | ||
| Q2 23 | $2.7M | $0 | ||
| Q2 22 | $16.4M | — |
| Q2 25 | $1.8M | — | ||
| Q2 24 | $123.0K | $484.0K | ||
| Q2 23 | $-1.0M | $-18.5M | ||
| Q2 22 | $-11.0M | — |
| Q2 25 | 53.3% | — | ||
| Q2 24 | 55.6% | 83.4% | ||
| Q2 23 | 44.7% | — | ||
| Q2 22 | 9.2% | — |
| Q2 25 | 11.9% | — | ||
| Q2 24 | 2.7% | -107.0% | ||
| Q2 23 | -27.7% | — | ||
| Q2 22 | -13.7% | — |
| Q2 25 | 64.2% | — | ||
| Q2 24 | 5.1% | 9.0% | ||
| Q2 23 | -36.7% | — | ||
| Q2 22 | -67.1% | — |
| Q2 25 | $0.03 | — | ||
| Q2 24 | $0.00 | $0.00 | ||
| Q2 23 | $-0.02 | $-0.02 | ||
| Q2 22 | $-0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $9.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.6M | $13.9M |
| Total Assets | $23.2M | $64.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $4.1M | — | ||
| Q2 24 | $1.6M | $9.6M | ||
| Q2 23 | $6.9M | $10.1M | ||
| Q2 22 | $9.2M | — |
| Q2 25 | $8.6M | — | ||
| Q2 24 | $6.6M | $13.9M | ||
| Q2 23 | $7.4M | $21.1M | ||
| Q2 22 | $9.4M | — |
| Q2 25 | $23.2M | — | ||
| Q2 24 | $17.6M | $64.6M | ||
| Q2 23 | $28.8M | $58.9M | ||
| Q2 22 | $136.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.4M |
| Free Cash FlowOCF − Capex | — | $-25.5M |
| FCF MarginFCF / Revenue | — | -472.8% |
| Capex IntensityCapex / Revenue | — | 1.1% |
| Cash ConversionOCF / Net Profit | — | -52.56× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q2 24 | — | $-25.4M | ||
| Q2 23 | — | $-17.7M | ||
| Q2 22 | — | — |
| Q2 25 | — | — | ||
| Q2 24 | — | $-25.5M | ||
| Q2 23 | — | $-17.8M | ||
| Q2 22 | — | — |
| Q2 25 | — | — | ||
| Q2 24 | — | -472.8% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | — | — | ||
| Q2 24 | — | 1.1% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | — | — | ||
| Q2 24 | — | -52.56× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
